Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clomiphene (also known as clomifene) is a nonsteroidal, orally administered selective estrogen receptor modulator (SERM) used primarily to induce ovulation in women with infertility due to anovulation, such as those with polycystic ovary syndrome. It acts by binding to estrogen receptors in the hypothalamus and pituitary, blocking negative feedback of endogenous estrogens and thereby increasing the release of gonadotropins (FSH and LH), which stimulate follicular development and ovulation. The drug consists of two geometric isomers—zuclomiphene (cis) and enclomiphene (trans)—with mixed estrogen agonist/antagonist effects. Besides female infertility, it is sometimes used off-label for male infertility, menstrual abnormalities, fibrocystic breast disease, persistent lactation, and hypogonadism in men[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomiphene.